Date July 27-31｜On-demand
Venue Online event platform
Bioeconomy is defined as “an economy where the basic building blocks for materials, chemicals, and energy are derived from renewable biological resources.”
Jung-Keug Park, Co-Chair of AFOB Division of Bioindustry Promotion and Bioeducation
Australia is a powerhouse for science and innovation, with excellent research facilities and a strong but flexible regulatory regime for pharmaceutical innovation. Australia is also regarded as one of the best places in the world to conduct clinical trials, with strengths in oncology, neurology and ophthalmology. This session will highlight the vibrant health and medical research ecosystem in Australia, featuring Australian state showcases to highlight the Australian health and biomedical ecosystem. As an innovative biotech leader, Australia is an ideal environment to research, develop and scale personalized medicines.
Jenny Bloomfield, Representative, Australian Office
Life Science Queensland
South Australia, Department for Trade and Investment
Western Australia Life Science Innovation
During the Covid pandemic years, India’s biotech companies demonstrated global leadership by producing over 2 billion doses of various COVID-19 vaccines and adding to the availability to vulnerable countries without vaccine manufacturing capabilities through the Covax program.
Biotechnology research and development is a complex, long gestation and resource intensive process. Also, innovation and speed are essential and companies seek to de-risk development and manufacturing costs by using competent partners around the world. India’s biotechnology companies are filling the global need for Contract Development and Manufacturing Organizations (CDMOs) for a wide range of biopharma products. India’s biotech CDMOs are emerging as reliable partners to help the global pharmaceutical industry with their specialized expertise in manufacturing and various steps involved in the entire value chain as affordable and reliable partners to lower the risk of capital deployment. This session will show case FOUR such companies from India that offer, with their integrated facilities across the biotech/pharma value chain, a wide range of development and manufacturing capabilities as reliable partners to the global pharmaceutical industry.
Dr. P M Murali, President, ABLE Council of Presidents
Susheel Umesh, Chief Commercial Officer- Emerging Markets, Biocon Biologics
The exponential advancement of biotechnology in recent years has enabled its application in all industrial sectors, and under the name of the bioeconomy, while aiming to expand its market, it is increasingly being used as a means to solve numerous social issues. In line with this growing importance of the bioeconomy, the government of Japan has released the Bioeconomy Strategy in 2019, concentrating on the formation of networks and the promotion of open innovation based on the biocommunity as one of its focused points. In addition, pharmaceutical and other companies, which are aggressively seeking to enhance their own R&D activities through open innovation, are increasing their importance of alliances with other companies and networks for finding partners. In light of this circumstances, we have planned this session to introduce Japan's Bioeconomy Strategy and the activities of the two global biocommunities formed in accordance with this strategy, and to have two leading Japanese pharmaceutical companies speak about their open innovations. We hope that session will help you accelerate collaborations with Japanese organizations and companies.
Moderator: Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association
Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association
This session showcases the rapidly evolving Singapore biotech ecosystem, focus areas, growing funding and vast support network. Further, the session will showcase four successful homegrown Singapore biotech companies: Hummingbird Bioscience, Engine Biosciences, DotBio and MediSix Therapeutics.
Danny Soon, Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore; Executive Director, Singapore Clinical Research Institute
The UK has long been a world-leader for innovation in life sciences. That is why so many of the great breakthroughs in this field – like Sir Alexander Fleming’s discovery of penicillin and the discovery of the structure of DNA and antibody therapies – have happened here. With advances in our understanding of biological systems, higher-speed computing and breakthroughs in genomics, we have opened up untold possibilities and more. The UK’s rich history as a centre for science and innovation in Life Sciences is underpinned by long-standing infrastructure investments by the National Institute for Health Research (NIHR), UK Research and Innovation (UKRI) and the medical research charities; the deep science skills base across industry, academia, the NHS; and the ingenuity and drive of industry – from the world’s largest Life Sciences companies to the smallest SMEs.
In this video, we will explain why choose UK life sciences and also showcasing 9 UK innovations listed in alphabetical order- AMT, Astrazeneca, Evaluate, GSK, Gyrogear, iotaSciences, Leo Cancer Care, Oxford Instruments and Yourgene Health.
Charlotte Mackay, British Office Taipei
British Office Taipei - Department for International Trade
Amy Brown, Deputy Editor, Evaluate Vantage Cem Baydar, Chief Consulting Officer, Evaluate
Mick Stanley, General Manager, GlaxoSmithKline Taiwan
Mrs. Karolina Karl – Head of Life Sciences team, Invest Lithuania
Lithuania, a small Baltic nation with a population of around 2.8 million people, has shifted its focus to Life Sciences. In this session, governmental agency responsible for attracting foreign direct investment to the country - Invest Lithuania’s, Head of Life Sciences team Karolina Karl will discuss Lithuania’s journey to becoming an independent state driven by innovation and how Life Sciences are seen as a key part of the national strategy for future economic growth. With this aim, the government set an ambitious goal to increase the GDP contribution of the Life Sciences industry from 2.5% to 5% by 2030.
To date, Lithuania has built a well-functioning business ecosystem where it takes only a few days to register a biotech company or get construction permits, all through digitalized systems aligned with EU regulations and norms. The Baltic champion also offers some of the most competitive FDI tax incentives in Europe, including one of the lowest patent box tax as well as 20 years corporate profit tax release for large scale investments. Multinational companies including Thermo Fisher, Hollister, Dexcom, Esco, Teva and others have already taken advantage of the unbeatable conditions and world-class talent pool available locally.
This session will illustrate what Lithuania can offer through stories covering the research of a local Vilnius University Professor Virginijus Siksnys, who was one of the co-founders of the CRISPR Cas9 technology, alongside Nobel Prize winners Emmanuelle Charpentier and Jennifer A. Doudna. In addition to that, you will get to know what drug was developed by Teva’s Lithuanian team and how Thermo Fisher has been growing in the market for the last 20 years.
Come and explore a new gateway to Europe!